Overcoming immune evasion with innovative multi-target approaches for glioblastoma

被引：0

作者：

Su, Hai ^{[1
]}

Peng, Yin ^{[1
]}

Wu, Yilong ^{[1
]}

Zeng, Xiaoli ^{[2
,3
,4
]}

机构：

[1] Chongqing Med Univ, Dept Neurosurg, Yongchuan Hosp, Chongqing, Peoples R China

[2] Gannan Med Univ, Affiliated Hosp 1, Dept Oncol, Ganzhou, Jiangxi, Peoples R China

[3] Gannan Med Univ, Affiliated Hosp 1, Jiangxi Flagship Oncol Dept Synergy Chinese & West, Ganzhou, Jiangxi, Peoples R China

[4] Gannan Med Univ, Affiliated Hosp 1, Jiangxi Clin Med Res Ctr Canc, Dept Oncol, Ganzhou, Jiangxi, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷

关键词：

glioblastoma; immune evasion; immunotherapy; PD-1; immune checkpoint; TUMOR-INFILTRATING LYMPHOCYTES; RANDOMIZED PHASE-III; REGULATORY T-CELLS; INDOLEAMINE 2,3-DIOXYGENASE; RECURRENT GLIOBLASTOMA; INHIBITORY MOLECULES; CHECKPOINT BLOCKADE; UP-REGULATION; GLIOMA; EXPRESSION;

D O I：

10.3389/fimmu.2025.1541467

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Glioblastoma (GBM) cells leverage complex endogenous and environmental regulatory mechanisms to drive proliferation, invasion, and metastasis. Tumor immune evasion, facilitated by a multifactorial network, poses a significant challenge to effective therapy, as evidenced by the limited clinical benefits of monotherapies, highlighting the adaptive nature of immune evasion. This review explores glioblastoma's immune evasion mechanisms, the role of ICIs in the tumor microenvironment, and recent clinical advancements, offering theoretical insights and directions for monotherapy and combination therapy in glioblastoma management.

引用

页数：8

共 50 条

[21] Towards multi-target glioblastoma therapy: Structural, distribution, and functional insights into protein target candidates
Anas, Emily
Hoover, Emma
Ille, Anetta L.
Ille, Alexander M.
Amico-Ruvio, Stacy
BRAIN RESEARCH, 2024, 1822
[22] Overcoming TGFβ-mediated immune evasion in cancer
Daniele V. F. Tauriello
Elena Sancho
Eduard Batlle
Nature Reviews Cancer, 2022, 22 : 25 - 44
[23] Overcoming TGFβ-mediated immune evasion in cancer
Tauriello, Daniele V. F.
Sancho, Elena
Batlle, Eduard
NATURE REVIEWS CANCER, 2022, 22 (01) : 25 - 44
[24] Overcoming tumor immune evasion with an unique arbovirus
Bruce Lyday
Tony Chen
Santosh Kesari
Boris Minev
Journal of Translational Medicine, 13
[25] Overcoming tumor immune evasion with an unique arbovirus
Lyday, Bruce
Chen, Tony
Kesari, Santosh
Minev, Boris
JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
[26] Overcoming immune evasion in pediatric brain tumors
Garancher, Alexandra
Suzuki, Hiromichi
Haricharan, Svasti
Masihi, Meher B.
Rusert, Jessica M.
Norris, Paula S.
Carrette, Florent
Romero, Megan M.
Morrissy, Sorana A.
Skowron, Patryk
Cavalli, Florence M. G.
Farooq, Hamza
Ramaswamy, Vijay
Morcavallo, Alaide
Henderson, Jacob J.
Olson, James M.
Cho, Yoon-Jae
Li, Xiao-Nan
Chesler, Louis
Marra, Marco A.
Becher, Oren J.
Bradley, Linda M.
Ware, Carl F.
Taylor, Michael D.
Wechsler-Reya, Robert J.
CANCER RESEARCH, 2020, 80 (14) : 23 - 23
[27] Strategies for Overcoming Immune Evasion in Bladder Cancer
Shin, Juhyun
Park, Jeong Won
Kim, Seon Young
Lee, Jun Ho
Choi, Wahn Soo
Kim, Hyuk Soon
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
[28] Overcoming Immune Evasion in Advanced Prostate Cancer
Alimonti, Andrea
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 533 - 535
[29] Overcoming immune system evasion by personalized immunotherapy
Soares, Kevin C.
Zheng, Lei
Ahuja, Nita
PERSONALIZED MEDICINE, 2014, 11 (06) : 561 - 564
[30] In silico repurposing of FDA-approved drugs as multi-target inhibitors of glioblastoma
Salaam, Ridwan Abiodun
Afolayan, Funmilayo I. D.
Olaniyi, Damilare Adebayo
Oladokun, Sayo Ebenezer
Ebuh, Rachael Pius
Oyetunji, Ridwan Abiola
SCIENTIFIC AFRICAN, 2025, 27

← 1 2 3 4 5 →